Navigation Links
ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
Date:1/31/2008

SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), announced today that data from preclinical studies of ANX-201, the Company's broad spectrum antiviral product candidate, has been accepted for presentation at the Keystone Symposia HIV Pathogenesis Conference, which takes place March 27-April 1, 2008 in Banff, Alberta. The HIV Pathogenesis Conference is part of the Keystone Symposia Global Health Series, which is supported by the Bill & Melinda Gates Foundation.

The poster presentation entitled "The pyrophosphate analogue thiophosphonoformic acid confers a favorable HIV resistance profile," is scheduled to be presented on March 30, 2008. The presentation will highlight results of in vitro infectivity assays that demonstrate a unique resistance profile for ANX-201 that suggests suppression of resistance to nucleoside reverse transcriptase inhibitors (NRTIs), a commonly used class of drugs. The potential clinical benefit of ANX-201 when used as part of combination therapy with NRTIs in resistant HIV-infected patients will also be discussed.

About ANX-201

ANX-201 (thiophosphonoformic acid) is a pyrophosphate analog and member of a new class of reverse transcriptase inhibitor (RTI) for treatment of resistant HIV-infected patients. ANX-201 has shown activity against HIV drug-resistant clinical isolates in preclinical studies. The resistance profile of ANX-201 is unique among approved RTIs and has been shown to resensitize NRTI-resistant viruses. In preclinical studies, antiretroviral activity of ANX-201 has demonstrated synergistic activity with NRTIs suggesting potential clinical benefits of combination therapy. In other preclinical studies, ANX-201 has shown broad-spectrum antiviral a
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/8/2008)...of clinical evidence demonstrating the efficacy an... of stress urinary inconti...swire/ -- A new study published in the,August issu...data of an,11-year follow up study on the safety a...) as a treatment for stress urinary incontinence (...
(Date:9/6/2008)...ng 95 Percent or Greater Concordance Compared to F...Breast -, - Company to Include Reporting for HER2 ... Reports by End of 2008 -, REDWOOD CITY, C...ealth,Inc. (Nasdaq: GHDX ) today announced resul...e reporting for HER2 gene expression, as measured ...
(Date:9/5/2008)... 5 /- CEL-SCI Corporation,(... rheumatoid arthritis data,at the Marcus Evans con...presented by Dr. Daniel Zimmerman, Senior Vice Pre..., indicate that CEL-SCI,s rheumatoid,arthritis vac...ssue damage,caused by rheumatoid arthritis in an a...
(Date:9/4/2008)...han designation for the treatment of Acute Myeloid...ON, N.J., Sept. 4 /- Celator Pharmace...Administration (FDA) has granted orphan,drug desig...me Injection,for the treatment of Acute Myeloid Le...conduct two randomized Phase 2,studies with CPX-35...
Breaking Medicine Technology:New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence 2New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence 3Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 2Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 3Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 4Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 5Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 2Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 3Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 4Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351 2Long Term Followup in Phase 3 CLL Trial Shows Genasense 28R 29 is Associated with Significantly Increased Survival in All Responders 2221 1Long Term Followup in Phase 3 CLL Trial Shows Genasense 28R 29 is Associated with Significantly Increased Survival in All Responders 2221 2Long Term Followup in Phase 3 CLL Trial Shows Genasense 28R 29 is Associated with Significantly Increased Survival in All Responders 2221 3Long Term Followup in Phase 3 CLL Trial Shows Genasense 28R 29 is Associated with Significantly Increased Survival in All Responders 2221 4InterMune Announces Start of 14 Day Triple Combination Study of ITMN 191 in Patients With Chronic Hepatitis C 2219 1InterMune Announces Start of 14 Day Triple Combination Study of ITMN 191 in Patients With Chronic Hepatitis C 2219 2InterMune Announces Start of 14 Day Triple Combination Study of ITMN 191 in Patients With Chronic Hepatitis C 2219 3InterMune Announces Start of 14 Day Triple Combination Study of ITMN 191 in Patients With Chronic Hepatitis C 2219 4Wyeth Receives FDA Fast Track Designation for its 13 valent Pneumococcal Conjugate Vaccine for Infants and Toddlers 2217 1Wyeth Receives FDA Fast Track Designation for its 13 valent Pneumococcal Conjugate Vaccine for Infants and Toddlers 2217 2Wyeth Receives FDA Fast Track Designation for its 13 valent Pneumococcal Conjugate Vaccine for Infants and Toddlers 2217 3Wyeth Receives FDA Fast Track Designation for its 13 valent Pneumococcal Conjugate Vaccine for Infants and Toddlers 2217 4Type of Tomato Product Determines Power Against Prostate Cancer 20497 1Type of Tomato Product Determines Power Against Prostate Cancer 20497 2Type of Tomato Product Determines Power Against Prostate Cancer 20497 3
(Date:9/8/2008)...all sizes a tool to help them select ...t. 8 /PRNewswire/ -- In a report released this wee... earned top scores for,ambulatory electronic healt...rovider Industry Short List: Ambulatory,Electronic...entifies the,leading ambulatory electronic health ...
(Date:9/8/2008)...ire/ -- Laser scalpels, arthroscopic,surgery, geno...s --,veterinary medicine is quickly expanding into...has a side benefit; it,s improving medicine for,pe... advanced care for their pets to,treat diseases li...d,cancer, according to the American Veterinary Med...
(Date:9/8/2008)...ls, Inc., (d/b/a NZyme) a company established in 2...se" (PN20K) Sept. 2008. Dr. Ralph E. Holswor...riday the company will begin to market the new lin... "PN20K" to North and South America. , ...ber 8, 2008 -- "PN20K" is a pro-fibrinol...
(Date:9/7/2008)... Students and University Leaders to, Join the Smok...Big Tobacco, WASHINGTON, Sept. 8 /PRNewswire-USNe...aggressive tobacco industry marketing tactics as o...eport released today by the,American Lung Associat...w of the current status of,tobacco use and policie...
Breaking Medicine News(10 mins):Health News:Intergy EHR by Sage on Short List of EMR Market Leaders 2Health News:Intergy EHR by Sage on Short List of EMR Market Leaders 3Health News:High-Tech Vet Medicine Saving Lives of Pets and People 2Health News:NZymeCeuticals Announces the Introduction of New Bulk Ingredient 'Platinum Nattokinase' (PN20K) to Dietary Supplement Industry 2Health News:Big Tobacco's Grip on Colleges and Students Loosens, But Still Holding Strong: New Report Examines Trends on Campuses 2Health News:Big Tobacco's Grip on Colleges and Students Loosens, But Still Holding Strong: New Report Examines Trends on Campuses 3Health News:Big Tobacco's Grip on Colleges and Students Loosens, But Still Holding Strong: New Report Examines Trends on Campuses 4
...y Cancer Research UK to mark Sun Awareness Week fo...th melanoma is making it the most dangerous form o...ere released, the male deaths in Britain from mela... past decade to more than 1,000 a year. It showed ...
... levied on relatives and friends of patients towar...tudy conducted by patient representative forums ha...ll as relaxing bans on personal mobile phone use. ...s high as 1.50 pounds a minute were being charged ...
...ration in injured nerve fibres in the mature centr...d researchers worldwide, //but researchers at Chil... occurring growth factor Oncomodulin which could w...ases like glaucoma, tumors, trauma, spinal cord in...
...alth will encourage women to give birth to their b...ption. //It said that it wanted to dispel myths th...nto the world. Health Secretary Patricia Hewitt h...ing for a commission to probe how births can be ma...
Other Medicine News:Health News:High Death Rate In UK Due To Melanoma Skin Cancer 2Health News:Patients Indignant at Exorbitant Phone Bills from Hospital 2Health News:'Oncomodulin'- Path To Nerve Regeneration 2
ELISA kit for CMV CAP M.
Herpes Simplex Virus 1 IgG ELISA.
Blunt tipped forceps with tungsten carbide treated jaws for enhanced gripping and removal of large sized foreign bodies.
Blunt tipped forceps with long thin tips (3 mm) angled at approximately 120. For grasping of subretinal membranes. Color Coding: Gold.
Medicine Products: